Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interle
Tweet Content
Phase III Trials Back Bimekizumab for Spondyloarthritis
Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.
https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off